Abstract
Children born small for gestational age (SGA) who do not show catch-up in the first 2 years generally remain short for life. Although the majority of children born SGA are not growth hormone (GH) deficient, GH treatment is known to improve average growth in these children.
Early studies using GH in children born SGA demonstrated increased height velocity, but these effects tended to be short-term with effects decreasing when GH treatment stopped. With refined GH regimens, significant effects on height have been shown, with gains of approximately 1 standard deviation score after 2 years. Studies have also shown that long-term continuous GH therapy can significantly increase final height to within the normal range. GH treatment of children born SGA does not appear to unduly affect bone age or pubertal development. Growth prediction models have been used to identify various factors involved in the response to GH therapy with ageat start, treatment duration, and GH dose showing strong effects. Genetic factors such as the exon 3 deletion of the GH receptor may contribute to short stature of children born SGA and may also be involved in the responsiveness to GH treatment, but there remain other unknown genetic and/or environmental factors. No unexpected safety concerns have arisen in GH therapy trials. In particular, no long-term adverse effects have been seen for glucose metabolism, and positive effects have been shown for lipid profiles and blood pressure.
GH treatment in short children born SGA has shown a beneficial, growthpromoting effect in both the short-and long-term, and has become a recognized indication in both the US and Europe. Further studies on individualized treatment regimens and long-term safety are ongoing.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Clayton PE, Cianfarani S, Czernichow P, Johannsson G, Rapaport R, Rogol A. Management of the child born small for gestational age child (SGA) through to adulthood: a consensus statement of the International Societies of Paediatric Endocrinology and the Growth Hormone Research Society. J Clin Endocrinol Metab. 2007;92:804–810.
Ester W, Bannink E, van Dijk M, et al. Subclassification of small for gestational age children with persistent short stature: growth patterns and response to GH treatment. Horm Res. 2007;69:89–98.
Geva R, Eshel R, Leitner Y, Valevski AF, Harel S. Neuropsychological outcome of children with intrauterine growth restriction: a 9-year prospective study. Pediatrics. 2006;118:91–100.
Brandt I, Sticker EJ, Lentze MJ. Catchup growth of head circumference of very low birth weight, small for gestational age preterm infants and mental development to adulthood. J Pediatr. 2003;142:463–468.
Frisk V, Amsel R, Whyte HE. The importance of head growth patterns in predicting the cognitive abilities and literacy skills of small-for-gestational-age children. Dev Neuropsychol. 2002;22:565–593.
Saenger P, Czernichow P, Hughes I, Reiter EO. Small for gestational age: short stature and beyond. Endocrine Rev. 2007;28:219–251.
Crane JP, Kopta MM. Prediction of intrauterine growth retardation via ultrasonically measured head/abdominal circumference ratios. Obstet Gynecol. 1979;54:597–601.
Lee PA, Chernausek SD, Hokken-Koelega AC, Czernichow P. International Small for Gestational Age Advisory Board consensus development conference statement: management of short children born small for gestational age, April 24–October 1, 2001. Pediatrics. 2003;111:1253–1261.
Pollack RN, Divon MY. Intrauterine growth retardation: definition, classification, and etiology. Clin Obstet Gynecol. 1992;35:99–107.
Pfab T, Slowinski T, Godes M, Halle H, Priem F, Hocher B. Low birth weight, a risk factor for cardiovascular diseases in later life, is already associated with elevated fetal glycosylated hemoglobin at birth. Circulation. 2006;114:1687–1692.
Barker DJ, Gluckman PD, Godfrey KM, Harding JE, Owens JA, Robinson JS. Fetal nutrition and cardiovascular disease in adult life. Lancet. 1993;341:938–941.
Villar J, Belizan JM. The timing factor in the pathophysiology of the intrauterine growth retardation syndrome. Obstet Gynecol Surv. 1982;37:499–506.
Chernausek SD. Mendelian genetic causes of the short child born small for gestational age. J Endocrinol Invest. 2006;29(suppl. 1):16–20.
Clausson B, Cnattingius S, Axelsson O. Preterm and term births of small for gestational age infants: a populationbased study of risk factors among nulliparous women. Br J Obstet Gynaecol. 1998;105:1011–1017.
Lindsay RS, Dabelea D, Roumain J, Hanson RL, Bennett PH, Knowler WC. Type 2 diabetes and low birth weight: the role of paternal inheritance in the association of low birth weight and diabetes. Diabetes. 2000;49:445–449.
Gluckman PD, Harding JE. The physiology and pathophysiology of intrauterine growth retardation. Horm Res. 1997;48 (suppl. 1):11–16.
Magnus P, Bakketeig LS, Hoffman H. Birth weight of relatives by maternal tendency to repeat small-for-gestational-age (SGA) births in successive pregnancies. Acta Obstet Gynecol Scand Suppl. 1997;165:35–38.
van Pareren Y, Mulder P, Houdijk M, Jansen M, Reeser M, Hokken-Koelega A. Adult height after long-term, continuous growth hormone (GH) treatment in short children born small for gestational age: results of a randomized, double-blind, doseresponse GH trial. J Clin Endocrinol Metab. 2003;88:3584–3590.
Carrascosa A, Vicens-Calvet E, Yeste D, Espadero RM, Ulied A, SGA Spanish Collaborative Group. Children born small for gestational age (SGA) who fail to achieve catch up growth by 2-8 years of age are short from infancy to adulthood. Data from a cross-sectional study of 486 Spanish children. Pediatr Endocrinol Rev. 2006;4:15–27.
de Zegher F, Albertsson-Wikland K, Wollmann HA, et al. Growth hormone treatment of short children born small for gestational age: growth responses with continuous and discontinuous regimens over 6 years. J Clin Endocrinol Metab. 2000;85:2816–2821.
Leger J, Limoni C, Collin D, Czernichow P. 1998 prediction factors in the determination of final height in subjects born small for gestational age. Pediatr Res. 1998;43: 808–812.
Leger J, Noel M, Limal JM, Czernichow P. Growth factors and intrauterine growth retardation. II. Serum growth hormone, insulin-like growth factor (IGF) I, and IGFbinding protein 3 levels in children with intrauterine growth retardation compared with normal control subjects: prospective study from birth to two years of age. Pediatr Res. 1996;40:101–107.
Iñiguez G, Ong K, Bazaes R, et al. Longitudinal changes in insulin-like growth factor-I, insulin sensitivity, and secretion from birth to age three years in small-forgestational-age children. J Clin Endocrinol Metab. 2006;91:4645–4649.
Verkauskiene R, Jaquet D, Deghmoun S, Chevenne D, Czernichow P, Lévy-Marchal C. Smallness for gestational age is associated with persistent change in insulinlike growth factor I (IGF-I) and the ratio of IGF-I/IGF-binding protein-3 in adulthood. J Clin Endocrinol Metab. 2005;90: 5672–5676.
Johnston LB, Dahlgren J, Leger J, et al. Association between insulin-like growth factor I (IGF-I) polymorphisms, circulating IGF-I, and pre-and postnatal growth in two European small for gestational age populations. J Clin Endocrinol Metab. 2003;88:4805–4810.
Arends N, Johnston L, Hokken-Koelega A, et al. Polymorphism in the IGF-I gene: clinical relevance for short children born small for gestational age (SGA). J Clin Endocrinol Metab. 2002;87:2720–2724.
Woods KA, Camacho-Hübner C, Barter D, Clark AJ, Savage MO. Insulin-like growth factor I gene deletion causing intrauterine growth retardation and severe short stature. Acta Paediatr Suppl. 1997;423:39–45.
Groom KM, Poppe KK, North RA, McCowan LM. Small-for-gestationalage infants classified by customized or population birthweight centiles: impact of gestational age at delivery. Am J Obstet Gynecol. 2007;197:239.e1–239.e5.
Westergaard HB, Langhoff-Roos J. Doppler ultrasonography in singleton pregnancies at risk of intrauterine growth retardation-a national estimate. Acta Obstet Gynecol Scand. 2002;81:534–539.
Botero D, Lifshitz F. Intrauterine growth retardation and long-term effects on growth. Curr Opin Pediatr. 1999;11:340–347.
Brook CG, Hindmarsh PC, Stanhope R. Growth and growth hormone secretion. J Endocrinol. 1988;119:179–184.
Hokken-Koelega AC, De Ridder MA, Lemmen RJ, Den Hartog H, De Muinck Keizer-Schrama SM, Drop SL. Children born small for gestational age: do they catch up? Pediatr Res. 1995;38:267–271.
Karlberg J, Albertsson-Wikland K, Kwan CW, Chan FY. Early spontaneous catchup growth. J Pediatr Endocrinol Metab. 2002;15(suppl. 5):1243–1255.
Albertsson-Wikland K, Karlberg J. Postnatal growth of children born small for gestational age. Acta Paediatr Suppl. 1997;423:193–195.
Karlberg J, Albertsson-Wikland K. Growth in full-term small-for-gestational-age infants: from birth to final height. Pediatr Res. 1995;38:733–739.
Chaussain JL, Colle M, Ducret JP. Adult height in children with prepubertal short stature secondary to intrauterine growth retardation. Acta Paediatr Suppl. 1994;399:72–73.
Hokken-Koèlega AC. Timing of puberty and fetal growth. Best Pract Res Clin Endocrinol Metab. 2002;16:65–71.
Lazar L, Pollak U, Kalter-Leibovici O, Pertzelan A, Phillip M. Pubertal course of persistently short children born small for gestational age (SGA) compared with idiopathic short children born appropriate for gestational age (AGA). Eur J Endocrinol. 2003;149:425–432.
Vicens-Calvet E, Espadero RM, Carrascosa A; Spanish SGA Collaborative Group. Small for gestational age. Longitudinal study of the pubertal growth spurt in children born small for gestational age without postnatal catch-up growth. J Pediatr Endocrinol Metab. 2002;15:381–388.
Jaquet D, Collin D, Lévy-Marchal C, Czernichow P. Adult height distribution in subjects born small for gestational age. Horm Res. 2004;62:92–96.
Arends NJ, Boonstra VH, Duivenvoorden HJ, Hofman PL, Cutfield WS, Hokken-Koelega AC. Reduced insulin sensitivity and the presence of cardiovascular risk factors in short prepubertal children born small for gestational age (SGA). Clin Endocrinol (Oxf). 2005;62:44–50.
Lévy-Marchal C, Czernichow P. Small for gestational age and the metabolic syndrome: which mechanism is suggested by epidemiological and clinical studies? Horm Res. 2006;65(suppl. 3):123–130.
Valdez R, Athens MA, Thompson GH, Bradshaw BS, Stern MP. Birthweight and adult health outcomes in a biethnic population in the USA. Diabetologia. 1994;37:624–631.
Barker DJ, Hales CN, Fall CH, Osmond C, Phipps K, Clark PM. Type 2 (non-insulindependent) diabetes mellitus, hypertension and hyperlipidaemia (syndrome X): relation to reduced fetal growth. Diabetologia. 1993;36:62–67.
Godfrey KM, Barker DJ. Fetal programming and adult health. Public Health Nutr. 2001;4:611–624.
Barker DJ, Eriksson JG, Forsén T, Osmond C. Fetal origins of adult disease: strength of effects and biological basis. Int J Epidemiol. 2002;31:1235–1239.
Barker DJ. The Wellcome Foundation Lecture, 1994. The fetal origins of adult disease. Proc Biol Sci. 1995;262:37–43.
Fall CH, Osmond C, Barker DJ, et al. Fetal and infant growth and cardiovascular risk factors in women. BMJ. 1995;310:428–432.
Hales CN, Barker DJ. The thrifty phenotype hypothesis. Br Med Bull. 2001;60:5–20.
Godfrey KM, Lillycrop KA, Burdge GC, Gluckman PD, Hanson MA. Epigenetic mechanisms and the mismatch concept of the developmental origins of health and disease. Pediatr Res. 2007;61:5R–10R.
Dennison E, Fall C, Cooper C, Barker D. Prenatal factors influencing long-term outcome. Horm Res. 1997;48(suppl. 1):25–29.
Hattersley AT, Tooke JE. The fetal insulin hypothesis: an alternative explanation of the association of low birth weight with diabetes and vascular disease. Lancet. 1999;353: 1789–1792.
Hattersley AT, Beards F, Ballantyne E, Appleton M, Harvey R, Ellard S. Mutations in the glucokinase gene of the fetus result in reduced birth weight. Nat Genet. 1998;19:268–270.
Valsamakis G, Kanaka-Gantenbein C, Malamitsi-Puchner A, Mastorakos G. Causes of intrauterine growth restriction and the postnatal development of the metabolic syndrome. Ann N Y Acad Sci. 2006;1092:138–147.
Leger J, Levy-Marchal C, Bloch J, et al. Reduced final height and indications for insulin resistance in 20 year olds born small for gestational age: regional cohort study. BMJ. 1997;315:341–347.
Jaquet D, Deghmoun S, Chevenne D, Collin D, Czernichow P, Lévy-Marchal C. Dynamic change in adiposity from fetal to postnatal life is involved in the metabolic syndrome associated with reduced fetal growth. Diabetologia. 2005;48:849–855.
Potau N, Gussinyé M, Sanchez Ufarte C, Riqué S, Vicens-Calvet E, Carrascosa A. Hyperinsulinemia in pre-and post-pubertal children born small for gestational age. Horm Res. 2001;56:146–150.
Veening MA, van Weissenbruch MM, Heine RJ, Delemarre-van de Waal HA. Beta-cell capacity and insulin sensitivity in prepubertal children born small for gestational age: influence of body size during childhood. Diabetes. 2003;52:1756–1760.
van Wassenaer A. Neurodevelopmental consequences of being born SGA. Pediatr Endocrinol Rev. 2005;2:372–377.
Lundgren EM, Cnattingius S, Jonsson B, Tuvemo T. Intellectual and psychological performance in males born small for gestational age with and without catch-up growth. Pediatr Res. 2001;50:91–96.
Roth S, Chang TC, Robson S, Spencer JA, Wyatt JS, Stewart AL. The neurodevelopmental outcome of term infants with different intrauterine growth characteristics. Early Hum Dev. 1999;55:39–50.
Schauseil-Zipf U, Hamm W, Stenzel B, Bolte A, Gladtke E. Severe intra-uterine growth retardation: obstetrical management and follow up studies in children born between 1970 and 1985. Eur J Obstet Gynecol Reprod Biol. 1989;30:1–9.
Kutschera J, Urlesberger B, Maurer U, Müller W. Small for gestational age-somatic, neurological and cognitive development until adulthood [in German]. Z Geburtshilfe Neonatol. 2002;206:65–71.
van der Reijden-Lakeman IE, de Sonneville LM, Swaab-Barneveld HJ, Slijper FM, Verhulst FC. Evaluation of attention before and after 2 years of growth hormone treatment in intrauterine growth retarded children. J Clin Exp Neuropsychol. 1997;19:101–118.
Berle JØ, Mykletun A, Daltveit AK, Rasmussen S, Dahl AA. Outcomes in adulthood for children with foetal growth retardation. A linkage study from the Nord-Trøndelag Health Study (HUNT) and the Medical Birth Registry of Norway. Acta Psychiatr Scand. 2006;113:501–509.
Larroque B, Bertrais S, Czernichow P, Léger J. School difficulties in 20-year-olds who were born small for gestational age at term in a regional cohort study. Pediatrics. 2001;108:111–115.
Paz I, Gale R, Laor A, Danon YL, Stevenson DK, Seidman DS. The cognitive outcome of full-term small for gestational age infants at late adolescence. Obstet Gynecol. 1995;85:452–456.
Lundgren EM, Cnattingius S, Jonsson B, Tuvemo T. Birth characteristics and different dimensions of intellectual performance in young males: a nationwide population-based study. Acta Paediatr. 2003;92:1138–1143.
Strauss RS. Adult functional outcome of those born small for gestational age: twentysix-year follow-up of the 1970 British Birth Cohort. JAMA. 2000;283:625–632.
Latal-Hajnal B, von Siebenthal K, Kovari H, Bucher HU, Largo RH. Postnatal growth in VLBW infants: significant association with neurodevelopmental outcome. J Pediatr. 2003;143:163–170.
Genotropin (somatropin [rDNA origin] for injection) prescribing information. Available at: http://www.pfizer.com/files/products/uspi_genotropin.pdf. Accessed August 2008.
Summary of Product Characteristics-Norditropin SimpleXx 5 mg/1.5 ml, Norditropin SimpleXx 10 mg/1.5 ml, Norditropin SimpleXx 15 mg/1.5 ml. Novo Nordisk Limited. June 2008. Available at: http://emc.medicines.org.uk/emc/assets/c/html/DisplayDoc.asp?DocumentID=2760. Accessed August 2008.
Summary of Product Characteristics-Humatrope 6 mg, 12 mg, 24 mg powder and solvent for injection. Eli Lilly and Company Limited. April 2008. Available at: http://emc.medicines.org.uk/emc/assets/c/html/DisplayDoc.asp?DocumentID=601. Accessed August 2008.
Butenandt O, Lang G. Recombinant human growth hormone in short children born small for gestational age. German Study Group. J Pediatr Endocrinol Metab. 1997;10:275–282.
Albanese A, Stanhope R. GH treatment induces sustained catch-up growth in children with intrauterine growth retardation: 7-year results. Horm Res. 1997;48:173–177.
Chaussain JL, Colle M, Landier F. Effects of growth hormone therapy in prepubertal children with short stature secondary to intrauterine growth retardation. Acta Paediatr Suppl. 1994;399:74–75.
Lenko HL, Leisti S, Perheentupa J. The efficacy of growth hormone in different types of growth failure. An analysis of 101 cases. Eur J Pediatr. 1982;138:241–249.
Tanner JM, Whitehouse RH, Hughes PC, Vince FP. Effect of human growth hormone treatment for 1 to 7 years on growth of 100 children, with growth hormone deficiency, low birthweight, inherited smallness, Turner’s syndrome, and other complaints. Arch Dis Child. 1971;46:745–782.
Tanner JM, Lejarraga H, Cameron N. The natural history of the Silver-Russell syndrome: a longitudinal study of thirty-nine cases. Pediatr Res. 1975;9:611–623.
Grunt JA, Howard CP, Daughaday WH. Comparison of growth and somatomedin C responses following growth hormone treatment in children with small-for-date short stature, significant idiopathic short stature and hypopituitarism. Acta Endocrinol (Copenh). 1984;106:168–174.
Foley TP Jr., Thompson RG, Shaw M, Baghdassarian A, Nissley SP, Blizzard RM. Growth responses to human growth hormone in patients with intrauterine growth retardation. J Pediatr. 1974;84 635–641.
Job JC, Chaussain JL, Job B, et al. Followup of three years of treatment with growth hormone and of one post-treatment year, in children with severe growth retardation of intrauterine onset. Pediatr Res. 1996;39: 354–359.
de Zegher F, Maes M, Gargosky SE, et al. High-dose growth hormone treatment of short children born small for gestational age. J Clin Endocrinol Metab. 1996;81: 1887–1892.
Chatelain P, Job JC, Blanchard J, et al. Dosedependent catch-up growth after 2 years of growth hormone treatment in intrauterine growth-retarded children. J Clin Endocrinol Metab. 1994;78:1454–1460.
Stanhope R, Ackland F, Hamill G, Clayton J, Jones J, Preece MA. Physiological growth hormone secretion and response to growth hormone treatment in children with short stature and intrauterine growth retardation. Acta Paediatr Scand Suppl. 1989;349:47–52.
Albertsson-Wikland K. Growth hormone secretion and growth hormone treatment in children with intrauterine growth retardation. Swedish Paediatric Study Group for Growth Hormone Treatment. Acta Paediatr Scand Suppl. 1989;349:5–41.
Rosilio M, Carel JC, Blazy D, Chaussain JL. Growth hormone treatment of children with short stature secondary to intrauterine growth retardation: effect of 2 years’ treatment and 2 years’ follow-up. Horm Res. 1997;48(suppl. 4):23–28.
van der Reijden-Lakeman I, Slijper FM, van Dongen-Melman JE, de Waal WJ, Verhulst FC. Self-concept before and after two years of growth hormone treatment in intrauterine growth-retarded children. Horm Res. 1996;46:88–94.
de Zegher F, Butenandt O, Chatelain P, et al. Growth hormone treatment of short children born small for gestational age: reappraisal of the rate of bone maturation over 2 years and metanalysis of height gain over 4 years. Acta Paediatr Suppl. 1997;423:207–212.
Ranke MB, Lindberg A. Growth hormone treatment of short children born small for gestational age or with Silver-Russell syndrome: results from KIGS (Kabi International Growth Study), including the first report on final height. Acta Paediatr Suppl. 1996;417:18–26.
Chernausek SD, Breen TJ, Frank GR. Linear growth in response to growth hormone treatment in children with short stature associated with intrauterine growth retardation: the National Cooperative Growth Study experience. J Pediatr. 1996;128:S22–S27.
Sas T, de Waal W, Mulder P, et al. Growth hormone treatment in children with short stature born small for gestational age: 5-year results of a randomized, double-blind, dose-response trial. J Clin Endocrinol Metab. 1999;84:3064–3070.
Sas T, Mulder P, Hokken-Koelega A. Body composition, blood pressure, and lipid metabolism before and during long-term growth hormone (GH) treatment in children with short stature born small for gestational age either with or without GH deficiency. J Clin Endocrinol Metab. 2000;85:3786–3792.
Chatelain P, de Zegher F, on behalf of the KIGS International board. Growth hormone treatment in children with intrauterine growth retardation and Silver-Russell syndrome. In: Ranke MB, Wilton P, eds. Growth Hormone Therapy in KIGS. Leipzig: Johann Ambrosius Barth Verlag; 1999: 305–319.
Fjellestad-Paulsen A, Simon D, Czernichow P. Short children born small for gestational age and treated with growth hormone for three years have an important catch-down five years after discontinuation of treatment. J Clin Endocrinol Metab. 2004;89: 1234–1239.
de Zegher F, Du Caju MV, Heinrichs C, et al. Early, discontinuous, high dose growth hormone treatment to normalize height and weight of short children born small for gestational age: results over 6 years. J Clin Endocrinol Metab. 1999;84:1558–1561.
Simon D, Leger J, Fjellestad-Paulsen A, Crabbé R, Czernichow P, SGA Study Group. Intermittent recombinant growth hormone treatment in short children born small for gestational age: four-year results of a randomized trial of two different treatment regimens. Horm Res. 2006;66:118–123.
Argente J, Gracia R, Ibáñez L, et al. Improvement in growth after two years of growth hormone therapy in very young children born small for gestational age and without spontaneous catch-up growth: results of a multicenter, controlled, randomized, open clinical trial. J Clin Endocrinol Metab. 2007;92:3095–3101.
Arends NJ, Boonstra VH, Mulder PG, et al. GH treatment and its effect on bone mineral density, bone maturation and growth in short children born small for gestational age: 3-year results of a randomized, controlled GH trial. Clin Endocrinol (Oxf). 2003;59:779–787.
Darendeliler F, Ranke MB, Bakker B, et al. Bone age progression during the first year of growth hormone therapy in pre-pubertal children with idiopathic growth hormone deficiency, Turner syndrome or idiopathic short stature, and in short children born small for gestational age: analysis of data from KIGS (Pfizer International Growth Database). Horm Res. 2005;63:40–47.
Job JC, Rolland A. Natural history of intrauterine growth retardation: pubertal growth and adult height [in French]. Arch Fr Pediatr. 1986;43:301–306.
Bozzola E, Lauriola S, Messina MF, Bona G, Tinelli C, Tatò L. Effect of different growth hormone dosages on the growth velocity in children born small for gestational age. Horm Res. 2004;61:98–102.
Ibáñez L, Jiménez R, de Zegher F. Early puberty-menarche after precocious pubarche: relation to prenatal growth. Pediatrics. 2006;117:117–121.
Ghirri P, Bernardini M, Vuerich M, et al. Adrenarche, pubertal development, age at menarche and final height of full-term, born small for gestational age (SGA) girls. Gynecol Endocrinol. 2001;15:91–97.
Boonstra V, van Pareren Y, Mulder P, Hokken-Koelega A. Puberty in growth hormone-treated children born small for gestational age (SGA). J Clin Endocrinol Metab. 2003;88:5753–5758.
Hokken-Koelega A, van Pareren Y, Arends N, Boonstra V. Efficacy and safety of long-term continuous growth hormone treatment of children born small for gestational age. Horm Res. 2004;62(suppl. 3):149–154.
van Pareren YK, Duivenvoorden HJ, Slijper FS, Koot HM, Hokken-Koelega AC. Intelligence and psychosocial functioning during long-term growth hormone therapy in children born small for gestational age. J Clin Endocrinol Metab. 2004;89:5295–5302.
Lagrou K, Vanderfaeillie J, Froidecoeur C, et al. Effect of 2 years of high-dose growth hormone therapy on cognitive and psychosocial development in short children born small for gestational age. Eur J Endocrinol. 2007;156:195–201.
Balsamo A, Tassoni P, Cassio A, et al. Response to growth hormone therapy in patients with growth hormone deficiency who at birth were small or appropriate in size for gestational age. J Pediatr. 1995; 126:474–477.
Albanese A, Azcona C, Stanhope R. Final height in children with IUGR receiving GH treatment. Horm Res. 1998;50(suppl. 3): P91. Abstract.
Coutant R, Carel JC, Letrait M, et al. Short stature associated with intrauterine growth retardation: final height of untreated and growth hormone-treated children. J Clin Endocrinol Metab. 1998;83:1070–1074.
Zucchini S, Cacciari E, Balsamo A, et al. Final height of short subjects of low birth weight with and without growth hormone treatment. Arch Dis Child. 2001;84:340–343.
Carel JC, Chatelain P, Rochiccioli P, Chaussain JL. Improvement in adult height after growth hormone treatment in adolescents with short stature born small for gestational age: results of a randomized controlled study. J Clin Endocrinol Metab. 2003;88:1587–1593.
Clayton P. Growth hormone normalizes adult height in short children born small for gestational age. Pfizer and NovoNordisk Symposium at the 42nd Annual Meeting of the European Society for Paediatric Endocrinology (ESPE), September 17, 2003; Ljubljana, Slovenia.
Rosilio M, Carel JC, Ecosse E, Chaussainon JL. Adult height of prepubertal short children born small for gestational age treated with GH. Eur J Endocrinol. 2005;152:835–843.
Albertsson-Wikland K, Boguszewski M, Karlberg J. Children born small for gestational age: postnatal growth and hormonal status. Horm Res. 1998;49 (suppl. 2):7–13.
de Zegher F, AIbertsson-Wikland K, Wilton P, et al. Growth hormone treatment of short children born small for gestational age: metaanalysis of four independent, randomized, controlled, multicentre studies. Acta Paediatr Suppl. 1996;417:27–31.
de Zegher F, Hokken-Koelega A. Growth hormone therapy for children born small for gestational age: height gain is less dose dependent over the long term than over the short term. Pediatrics. 2005;115:e458–e462.
Boguszewski M, Albertsson-Wikland K, Aronsson S, et al. Growth hormone treatment of short children born small-forgestational-age: the Nordic Multicentre Trial. Acta Paediatr. 1998;87:257–263.
Ranke MB, Lindberg A, Cowell CT, et al. Prediction of response to growth hormone treatment in short children born small for gestational age: analysis of data from KIGS (Pharmacia International Growth Database). J Clin Endocrinol Metab. 2003;88:125–131.
de Ridder MA, Stijnen T, Hokken-Koelega AC. Prediction model for adult height of SGA children at start of growth hormone treatment. J Clin Endocrinol Metab. 2008;93:477–483.
Rosenbloom AL. A mathematical model for predicting growth response to growth hormone replacement therapy a useful clinical tool or an intellectual exercise? J Clin Endocrinol Metab. 1999;84:1172–1173.
Schönau E, Westermann F, Rauch F, et al. A new and accurate prediction model for growth response to growth hormone treatment in children with growth hormone deficiency. Eur J Endocrinol. 2001;144:13–20.
Audí L, Esteban C, Carrascosa A, et al. Exon 3-deleted/full-length growth hormone receptor polymorphism genotype frequencies in Spanish short small-for-gestational-age (SGA) children and adolescents (n=247) and in an adult control population (n=289) show increased fl/fl in short SGA. J Clin Endocrinol Metab. 2006;91:5038–5043.
Dos Santos C, Essioux L, Teinturier C, Tauber M, Goffin V, Bougnères P. A common polymorphism of the growth hormone receptor is associated with increased responsiveness to growth hormone. Nat Genet. 2004;36:720–724.
Binder G, Baur F, Schweizer R, Ranke MB. The d3-growth hormone (GH) receptor polymorphism is associated with increased responsiveness to GH in Turner syndrome and short small-for-gestational-age children. J Clin Endocrinol Metab. 2006;91:659–664.
Tauber M, Ester W, Auriol F, et al. GH responsiveness in a large multinational cohort of SGA children with short stature (NESTEGG) is related to the exon 3 GHR polymorphism. Clin Endocrinol (Oxf). 2007;67:457–461.
Blum WF, Machinis K, Shavrikova EP, et al. The growth response to growth hormone (GH) treatment in children with isolated GH deficiency is independent of the presence of the exon 3-minus isoform of the GH receptor. J Clin Endocrinol Metab. 2006;91:4171–4174.
Pilotta A, Mella P, Filisetti M, et al. Common polymorphisms of the growth hormone (GH) receptor do not correlate with the growth response to exogenous recombinant human GH in GH-deficient children. J Clin Endocrinol Metab. 2006;91:1178–1180.
Carrascosa A, Audí L, Esteban C. et al. Growth hormone (GH) dose, but not exon 3-deleted/full-length GH receptor polymorphism genotypes, influences growth response to two-year GH therapy in short small-for-gestational-age children. J Clin Endocrinol Metab. 2008;93:147–153.
Czernichow P, Fjellestad-Paulsen A. Growth hormone in the treatment of short stature in young children with intrauterine growth retardation. Horm Res. 1998;49(suppl. 2): 23–27.
Blethen SL, Allen DB, Graves D, August G, Moshang T, Rosenfeld R. Safety of recombinant deoxyribonucleic acid-derived growth hormone: The National Cooperative Growth Study experience. J Clin Endocrinol Metab. 1996;81:1704–1710.
Darendeliler F, Karagiannis G, Wilton P. Headache, idiopathic cranial hypertension and slipped capital femoral epiphysis during growth hormone treatment: a safety update from the KIGS database. Horm Res. 2007;68(suppl. 5):41–47.
Cutfield WS, Lindberg A, Rapaport R, Wajnrajch MP, Saenger P. Safety of growth hormone treatment in children born small for gestational age: the US trial and KIGS analysis. Horm Res. 2006;65(suppl. 3): 153–159.
Phipps K, Barker DJ, Hales CN, Fall CH, Osmond C, Clark PM. Fetal growth and impaired glucose tolerance in men and women. Diabetologia. 1993;36:225–228.
McCance DR, Pettitt DJ, Hanson RL, Jacobsson LT, Knowler WC, Bennett PH. Birth weight and non-insulin dependent diabetes: thrifty genotype, thrifty phenotype, or surviving small baby genotype? BMJ. 1994;308:942–945.
Flanagan DE, Moore VM, Godsland IF, Cockington RA, Robinson JS, Phillips DI. Fetal growth and the physiological control of glucose tolerance in adults: a minimal model analysis. Am J Physiol Endocrinol Metab. 2000;278:e700–e706.
Morley R, Dwyer T. Fetal origins of adult disease? Clin Exp Pharmacol Physiol. 2001;28:962–966.
Veening MA, Van Weissenbruch MM, Delemarre-Van De Waal HA. Glucose tolerance, insulin sensitivity, and insulin secretion in children born small for gestational age. J Clin Endocrinol Metab. 2002;87:4657–4661.
Bozzola E, Lauriola S, Messina MF, et al. The risk of diabetes mellitus in children born small for gestational age and treated with recombinant growth hormone. J Pediatr Endocrinol Metab. 2005;18:63–67.
Cutfield WS, Jackson WE, Jefferies C, et al. Reduced insulin sensitivity during growth hormone therapy for short children born small for gestational age. J Pediatr. 2003;142:113–116.
de Zegher F, Ong K, van Helvoirt M, Mohn A, Woods K, Dunger D. Highdose growth hormone (GH) treatment in non-GH-deficient children born small for gestational age induces growth responses related to pretreatment GH secretion and associated with a reversible decrease in insulin sensitivity. J Clin Endocrinol Metab. 2002;87:148–151.
Jaquet D, Chevenne D, Czernichow P, Levy-Marchal C. No evidence for a major beta-cell dysfunction in young adults born with intrauterine growth retardation. Pediatr Diabetes. 2000;1:181–185.
de Zegher F, Ong KK, Ibáñez L, Dunger DB. Growth hormone therapy in short children born small for gestational age. Horm Res. 2006;65(suppl. 3):145–152.
Sas T, Mulder P, Aanstoot HJ, et al. Carbohydrate metabolism during long-term growth hormone treatment in children with short stature born small for gestational age. Clin Endocrinol (Oxf). 2001;54:243–251.
Hokken-Koelega AC, van Pareren Y, Sas T, Arends N. Final height data, body composition and glucose metabolism in growth hormone-treated short children born small for gestational age. Horm Res. 2003;60(suppl. 3):113–114.
Darendeliler F, Bundak R, Eryilmaz SK, Gunoz H, Bas F, Saka N. Follow-up height after discontinuation of growth hormone treatment in children with intrauterine growth retardation. J Pediatr Endocrinol Metab. 2002;15:795–800.
van Dijk M, Bannink EM, van Pareren YK, Mulder PG, Hokken-Koelega AC. Risk factors for diabetes mellitus type 2 and metabolic syndrome are comparable for previously growth hormone-treated young adults born small for gestational age (SGA) and untreated short SGA controls. J Clin Endocrinol Metab. 2007;92:160–165.
van Pareren Y, Mulder P, Houdijk M, Jansen M, Reeser M, Hokken-Koelega A. Effect of discontinuation of growth hormone treatment on risk factors for cardiovascular disease in adolescents born small for gestational age. J Clin Endocrinol Metab. 2003;88:347–353.
Tenhola S, Martikainen A, Rahiala E, Herrgârd E, Halonen P, Voutilainen R. Serum lipid concentrations and growth characteristics in 12-year-old children born small for gestational age. Pediatr Res. 2000;48:623–628.
van Dijk M, Mulder P, Houdijk M, et al. High serum levels of growth hormone (GH) and insulin-like growth factor-I (IGF-I) during high-dose GH treatment in short children born small for gestational age. J Clin Endocrinol Metab. 2006;91:1390–1396.
Cohen P, Clemmons DR, Rosenfeld RG. Does the GH-IGF axis play a role in cancer pathogenesis? Growth Horm IGF Res. 2000;10:297–305.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Jung, H., Rosilio, M., Blum, W.F. et al. Growth hormone treatment for short stature in children born small for gestational age. Adv Therapy 25, 951–978 (2008). https://doi.org/10.1007/s12325-008-0101-3
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12325-008-0101-3